Sushil Patel
Fortune : 10 M $ au 31/05/2026
Fortune : 10 M $ au 31/05/2026
Sushil Patel is currently Chief Executive Officer & Director at Replimune Group, Inc. since 2024 and Independent Director at Revolution Medicines, Inc. since 2022.
Formerly, Dr. Patel was Vice President-Franchise & Head-Oncology at Genentech, Inc. from 2018 to 2021.
Education includes an undergraduate degree from the University of Warwick in 1992, a graduate degree from Imperial College London in 1993, and a doctorate from the University of London in 1999.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 18/05/2026 | 747 492 ( 0,96% ) | 6 M $ | 31/05/2026 | |
| 31/03/2026 | 19 948 ( 0,01% ) | 3 M $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| REPLIMUNE GROUP, INC. | Directeur Général | 01/04/2024 |
| REVOLUTION MEDICINES, INC. | Directeur/Membre du Conseil | 16/06/2022 |
| Sociétés | Poste | Fin |
|---|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | 01/05/2021 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 6 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Imperial College London
Imperial College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of London
University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Warwick
University of Warwick Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Revolution Medicines, Inc.
Revolution Medicines, Inc. Pharmaceuticals: OtherHealth Technology Develops new therapies derived from natural products | Health Technology |
Replimune Group, Inc.
Replimune Group, Inc. BiotechnologyHealth Technology Develops oncolytic immunotherapies | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national